Compare IPCA Labs with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs BIOCON - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS BIOCON IPCA LABS/
BIOCON
 
P/E (TTM) x 23.7 68.0 34.8% View Chart
P/BV x 8.5 8.1 104.4% View Chart
Dividend Yield % 0.1 0.2 59.0%  

Financials

 IPCA LABS   BIOCON
EQUITY SHARE DATA
    IPCA LABS
Mar-19
BIOCON
Mar-19
IPCA LABS/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,042707 147.3%   
Low Rs590554 106.6%   
Sales per share (Unadj.) Rs298.691.9 324.9%  
Earnings per share (Unadj.) Rs35.016.7 209.5%  
Cash flow per share (Unadj.) Rs49.424.2 204.5%  
Dividends per share (Unadj.) Rs3.001.00 300.0%  
Dividend yield (eoy) %0.40.2 231.8%  
Book value per share (Unadj.) Rs247.1101.6 243.2%  
Shares outstanding (eoy) m126.35600.00 21.1%   
Bonus / Rights / Conversions ESOS--  
Price / Sales ratio x2.76.9 39.8%   
Avg P/E ratio x23.337.7 61.8%  
P/CF ratio (eoy) x16.526.1 63.3%  
Price / Book Value ratio x3.36.2 53.2%  
Dividend payout %8.66.0 143.2%   
Avg Mkt Cap Rs m103,108378,330 27.3%   
No. of employees `00013.46.1 219.2%   
Total wages/salary Rs m7,87411,653 67.6%   
Avg. sales/employee Rs Th2,807.08,994.3 31.2%   
Avg. wages/employee Rs Th585.81,900.7 30.8%   
Avg. net profit/employee Rs Th329.01,635.3 20.1%   
INCOME DATA
Net Sales Rs m37,73255,144 68.4%  
Other income Rs m5771,444 39.9%   
Total revenues Rs m38,30956,588 67.7%   
Gross profit Rs m6,90115,883 43.4%  
Depreciation Rs m1,8244,478 40.7%   
Interest Rs m189709 26.6%   
Profit before tax Rs m5,46512,140 45.0%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0422,123 49.1%   
Profit after tax Rs m4,42210,026 44.1%  
Gross profit margin %18.328.8 63.5%  
Effective tax rate %19.117.5 109.1%   
Net profit margin %11.718.2 64.5%  
BALANCE SHEET DATA
Current assets Rs m23,77848,228 49.3%   
Current liabilities Rs m10,97530,376 36.1%   
Net working cap to sales %33.932.4 104.8%  
Current ratio x2.21.6 136.5%  
Inventory Days Days10468 151.9%  
Debtors Days Days6686 77.1%  
Net fixed assets Rs m20,36864,130 31.8%   
Share capital Rs m2533,000 8.4%   
"Free" reserves Rs m30,97157,980 53.4%   
Net worth Rs m31,22460,980 51.2%   
Long term debt Rs m1,40915,766 8.9%   
Total assets Rs m45,507121,924 37.3%  
Interest coverage x30.018.1 165.3%   
Debt to equity ratio x00.3 17.4%  
Sales to assets ratio x0.80.5 183.3%   
Return on assets %10.18.8 115.1%  
Return on equity %14.216.4 86.1%  
Return on capital %17.316.8 103.4%  
Exports to sales %45.928.1 163.1%   
Imports to sales %16.618.9 88.1%   
Exports (fob) Rs m17,30815,506 111.6%   
Imports (cif) Rs m6,26610,399 60.3%   
Fx inflow Rs m17,30815,506 111.6%   
Fx outflow Rs m6,26610,399 60.3%   
Net fx Rs m11,0425,107 216.2%   
CASH FLOW
From Operations Rs m4,92311,546 42.6%  
From Investments Rs m-1,563-7,138 21.9%  
From Financial Activity Rs m-1,832-2,417 75.8%  
Net Cashflow Rs m1,5282,103 72.6%  

Share Holding

Indian Promoters % 45.9 40.4 113.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 11.4 8.4 135.7%  
FIIs % 25.3 10.7 236.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 19.9 87.4%  
Shareholders   36,892 109,995 33.5%  
Pledged promoter(s) holding % 2.1 0.0 5,350.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover from Day's Low to End Marginally Higher; Divi's Lab & Tata Motors Top Gainers(Closing)

Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors(Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

Don't Break These 5 Intraday Trading Rules(Fast Profits Daily)

Jun 1, 2021

To become a better intraday trader, follow these rules religiously.

The Most Visible Sign of India's Revival is on Two Wheels(Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

Rs 2 Trillion Stimulus Coming to a Stock Market Near You(Profit Hunter)

Jun 2, 2021

Get ready to profit from a massive stimulus that you've never seen before.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 14, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS